Comprehensive Insight Generation for Product Development

Target RWE generates complete, longitudinal datasets with the power of advanced analytics and rigorous causal inference methodologies to uncover deep insights on unmet needs, disease progression, and the efficacy and safety of new treatments in the real world.

Schedule a Meeting

A Partner for Your Clinical Programs

With strong expertise in liver disease, gastroenterology, and dermatology, Target RWE’s multi-stakeholder model allows you to develop robust disease protocols to inform study objectives and endpoints. Our registries contain all relevant disease state variables, which when combined with our digital collection of patient and clinician reported outcomes and biosamples provide a framework for decisions on study entry criteria and site selection – reducing unnecessary procedures and costly protocol amendments.

Healthcare Research & Development Abstract Stock Photo

Demonstrate Valuable Insights with
Real-World Evidence

Target RWE’s cross-sectional and longitudinally complete registries encompass diverse patient populations beyond those traditionally captured in Phase 2 and 3 trials, generating more meaningful evidence on product effectiveness and safety in the real world. We provide insights on natural history of disease, treatment patterns, disease progression and other clinical questions. Execute your publication strategy with confidence and speed by joining our unique collaborative academic model, which taps not just into our patient registries but our network of leading clinical investigators.

Phases of Drug Development Stock Photo

Comprehensive Treatment Comparisons for Informed Decision Making

Leverage our proven advanced analytics and diverse real-world data to evaluate comparative effectiveness, safety, and cost-effectiveness of new therapies. Target RWE’s patient-centered analyses utilize patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) measures to inform disease burden, empowering you with the insights necessary to improve healthcare utilization.

HEOR Abstract Visual Stock

Real-World Data for Regulatory Compliance & Safety

Target RWE’s fit-for-purpose longitudinal registries, ability to incorporate clinician-reported outcomes, and validated analytics software provide comprehensive solutions to meet FDA and pharmacovigilance risk assessment committee requests for new drug applications. Our research collaboration agreement with the FDA, combined with proven experience in meeting post marketing commitments and managing adjudication committees, enable us to be your trusted partner for regulatory decision-making.

Regulatory and Pharmacovigilance Stock

Patient Insights for Strategic Product Positioning

Target RWE's detailed patient journeys identify meaningful data points in disease that can inform your product positioning and marketing plan. Our large datasets, combined with novel analytical and causal inference methodology identify patient phenotypes with high unmet need, predict disease progression, and support identification of patients who will benefit most from your new therapy.

 

Commercial Analytics Stock

Fit-for-Purpose Registries for Advanced Research

Target RWE collaborates with a renowned network of clinical investigators to enroll large patient cohorts, capturing up to 5 years of retrospective and 15 years of prospective follow-up – creating some of the largest and most comprehensive real-world patient registries in the U.S.

280+
Academic & Community Sites
6+
Therapeutic Areas
25+
Disease Indications
10,000+
Patients with Biosamples
400,000+
Liver Disease Patients
200+
Publications

New Publications

title

Nonalcoholic Steatohepatitis (NASH)

Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality

title

Nonalcoholic Steatohepatitis (NASH)

Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups

title

Nonalcoholic Steatohepatitis (NASH)

Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort

title

Nonalcoholic Steatohepatitis (NASH)

Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort

title

Nonalcoholic Steatohepatitis (NASH)

A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

title

Nonalcoholic Steatohepatitis (NASH)

Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status

In the News

Nov 26 2024

ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World Registries

Nov 25 2024

New Target RWE Research Validates Updated Liver Disease Terminology in Children

Nov 18 2024

Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver Diseases

Oct 29 2024

DIA RWE 2024 Research: Presentation by Nuvan Rathnayaka

Contact

Have a Question or Want to Learn More?

Fill in your contact information & a member from our team will be in contact.

By Submitting this form, you consent to your information used by Target RWE for the purpose of contacting you to better understand your potential interest in Target RWE and/or its services. For more information, see our privacy policy.